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Abstract
Background: This observational study was designed to collect treatment outcomes data in patients using the
electronic Schizophrenia Treatment Adherence Registry (e-STAR).
Methods: Patients with schizophrenia or schizoaffective disorder in Australia who were prescribed risperidone
long-acting injection (RLAI) between 2003 and 2007 were assessed 12-months retrospectively, at baseline and 24-
months prospectively at 3-monthly intervals. The intent-to-treat population, defined as all patients who received at
least one dose of RLAI at baseline, was used for the efficacy and safety analyses.
Results: At total of 784 patients (74% with schizophrenia, 69.8% male) with a mean age of 37.1 ± 12.5 years and
10.6 ± 9.5 years since diagnosis were included in this Australian cohort. A significant improvement in mean Clinical
Global Impression - severity score was observed at 24-months (4.52 ± 1.04 at baseline, 3.56 ± 1.10 at 24-months).
Most of this improvement was seen by 3-months and was also reflected in mean Global Assessment of
Functioning score, which improved significantly at 24-months (42.9 ± 14.5 at baseline, 59 ± 15.4 at 24-months). For
patients still receiving RLAI at 24-months there was an increase from a mean baseline RLAI dose of 26.4 ± 5 mg to
43.4 ± 15.7 mg. Sixty-six percent of patients discontinued RLAI before the 24-month period–this decreased to 46%
once patients lost to follow-up were excluded.
Conclusion: Over the 24-month period, initiation of RLAI was associated with improved patient functioning and
illness severity in patients with schizophrenia or schizoaffective disorder. Improved outcomes were observed early
and sustained throughout the study.
Trial Registration: Clinical Trials Registration Number, NCT00283517.
Background
Approximately 800,000 hospital patient care days per
year are associated with treatment of schizophrenia or
schizoaffective disorders [1], which represents a signifi-
cant cost to the Australian healthcare system. There is
increasing evidence that a lack of adherence to pre-
scribed antipsychotic medication is a predictor for
relapse and subsequent hospitalisation [2,3]. Adherence
is increased by between 10 and 40% with the use of
long-acting injectable antipsychotics [4]. However, there
is concern regarding “the excessive use of [conventional]
depot medication as a crude response to the widespread
lack of adherence to oral medications” [5], given the
increased risk of tardive dyskinesia and higher levels of
extrapyramidal symptoms associated with these agents
compared to atypical antipsychotics [5]. Risperidone
long-acting injection (RLAI), the first long-acting formu-
lation of an atypical antipsychotic, offers an alternative
to conventional depot medication.
However, to date, little information is available on the
treatment, practice and outcomes potential of RLAI out-
side of the clinical trial setting. In 2002, the lack of
information outside of clinical trials led the National
Institute for Health and Clinical Excellence (NICE) in
the United Kingdom to recommend more high quality
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tions around the effects of atypical agents [6]. It was
upon this basis that the electronic Schizophrenia Treat-
ment Adherence Registry (e-STAR) database was devel-
oped to collect treatment outcomes of patients
prescribed RLAI for schizophrenia or schizoaffective
disorder.
The objectives of eSTAR were to: prospectively assess
medication usage patterns, to document clinical efficacy
and long-term treatment outcomes of RLAI, in a natura-
listic setting; to collect retrospective data, which allow
the evaluation of treatment outcomes with RLAI com-
pared to previous treatments, and to evaluate reasons
for initiating RLAI.
Methods
The e-STAR is a multi-country, observational study that
collects treatment outcomes data in patients with schi-
zophrenia using web-based electronic data-capture. The
p r i m a r yo b j e c t i v e so ft h es t u d yw e r et oe v a l u a t ed r u g
use patterns, efficacy and long-term treatment outcomes
of long-acting risperidone injection in a naturalistic set-
ting. Data collection was accomplished via a secure
web-based system. In order for the registry to capture
real-life treatment information, there were no formalised
diagnostic procedures, randomisation or treatment deci-
sions mandated in the protocol. Physicians based their
treatment decisions on their best medical judgment.
Data for the Spanish cohort have been published pre-
viously [7]. The present paper describes results from the
e-STAR study in Australia, which was collected between
October 2003 and March 2007 at 15 clinical sites across
Australia. The study was approved by the relevant insti-
tutional ethics committee at each centre, was conducted
in compliance with the Declaration of Helsinki, and
registered: Clinical Trials Registration Number,
NCT00283517. Ethics approval numbers for each of the
centres can be found in the Ethics Approval section at
the end of this manuscript.
Participants
Patients with schizophrenia or schizoaffective disorder
(diagnoses on the basis of DSM-IV criteria [8]) who
started treatment with RLAI at an in- or out-patient set-
ting during the course of their routine clinical manage-
ment were eligible to participate. Patients with co-
morbid psychiatric disorders were eligible to participate.
All participants provided written, informed consent
prior to any data collection, either personally, or via
their appointed legal guardian.
Antipsychotic therapy
Participants were prescribed RLAI according to the Aus-
tralian local label [9]. For risperidone naïve patients, it was
recommended that a test dose of immediate release oral
formulation was given to establish tolerability [9]. The
recommended starting dose for all patients was 25 mg
given intramuscularly every two weeks [9]. Sufficient anti-
psychotic therapy coverage was recommended during the
three-week lag period following the first RLAI injection
[9]. For patients switched from a long-acting depot medi-
cation, RLAI was initiated att h en e x ts c h e d u l e dd e p o t
injection time, with sufficient oral coverage required for 3-
weeks. Upward dose adjustments were recommended to
not be made more frequently than every four weeks [9].
Data collection
Data collection in the study has been described pre-
viously [7]. Briefly, however, three data collection peri-
ods were specified: retrospective, baseline and
prospective. The retrospective data were collected from
patient medical records from the treating hospital and/
or community mental health clinic for a period of 12-
months prior to initiation of RLAI. Baseline data were
collected at the time of initiation of RLAI. Prospective
data were collected every 3-months from baseline for a
period of 24-months.
Data collected during the retrospective period
included treatment and hospitalisation history. At base-
line (defined as the initiation of RLAI) the following
information was collected: patient demographics, illness
characteristics (using the Clinical Global Impression of
illness Severity [CGI-S [10]] and Global Assessment of
Functioning [GAF [8]]) including dose of RLAI, the rea-
son for RLAI initiation, other psychiatric medications,
and community treatment orders (CTO). Prospectively,
we collected information on CGI-S, GAF, psychiatric
hospitalisations, concomitant therapies, clinical dete-
rioration (defined as one of the following: partial or full
hospitalisation for exacerbation of psychotic symptoms;
need to increase level of care combined with an increase
in CGI-S of at least 2 points; the emergence of suicidal
or homicidal ideation; deliberate self harm, and violent
behaviours), treatment adherence and discontinuation,
compulsory treatment orders, and adverse events.
Statistical analyses
Data were entered directly into the web-based e-STAR
tool. Data presented here are based upon intent-to-treat
(ITT) and per protocol (PP) analyses of Australian
patients enrolled in this 24-month study. The ITT
population were those subjects who received at least
one injection of RLAI. The PP population were those
subjects who received RLAI at baseline and completed
the study (defined as having at least one recorded piece
of information 720 days (24-months) post baseline). The
PP population did not necessarily remain on RLAI for
the 24-month period. We did not use a last observation
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between the PP and ITT populations can only be made
at baseline. Safety data are presented for the ITT and
PP populations of Australian patients.
Descriptive statistics are reported for patient demo-
graphics, disease characteristics, treatment adherence,
treatment discontinuation, reasons for RLAI initiation,
RLAI dose, antipsychotic and other concomitant medi-
cations, and adverse events. Differences in the number
of hospitalisations were analysed using the signed-rank
test, while differences in length of hospitalisation were
compared using paired t-tests. Changes in medications
and clinical deterioration were calculated under the a
priori hypothesis of no change from baseline to 24-
months using the McNemar test. Changes in CGI-S and
GAF were compared using paired t-tests.
A Kaplan-Meier procedure was used to estimate the
percentage of patients who discontinued from RLAI in
the first 24-months following initiation. The first reason
for RLAI discontinuation was reported with descriptive
statistics.
Data are presented as mean (standard deviation)
unless otherwise noted. To adjust for multiple testing,
statistical significance was assigned where P < 0.001.
Results
Patient demographics
A total of 784 patients were available for inclusion in
the ITT analysis. The PP population consists of 359
patients. The demographic, baseline clinical characteris-
tics and previous hospitalisations of ITT and PP patients
a r es h o w ni nT a b l e1 .F o rt h o s ep a t i e n t si nt h eI T T
population with “other” diagnoses, the diagnoses
included schizophreniform (n = 13); delusional disorder
(n = 6); bipolar affective disorder (n = 4); psychosis (n =
4); “likely” schizophrenia (n = 1); and schizoaffective
with organic personality disorder (n = 1). The ITT and
PP were similar with respect to baseline demographics,
although those who completed the study (PP popula-
tion) had a longer duration of illness compared to the
whole (ITT) population.
The main reasons patients were initiated on RLAI
were due to adherence (51.8%), unacceptable tolerabil-
ity/adverse events (24.7%), and insufficient response
(14.3%). In the 3-months prior to initiation of RLAI,
most patients who were on antipsychotic medications
received oral atypical antipsychotics either as monother-
apy (27.0%) or in combination (13.4%); or were adminis-
tered a conventional depot medication either as
monotherapy (23.1%), or in combination (11.2%).
Treatment
The majority of patients in the ITT population were
initiated on 25 mg RLAI (90.8%). The mean dose at
baseline was 26.4 ± 5.0 mg with a median of 25 mg. At
24 months, the mean dose in patients still receiving
RLAI was 43.4 ± 15.7 mg with a median of 37.5 mg.
Slightly more than a third of patients had no dose
adjustments (38.0%); others subsequently went on to
have 1 (22.3%) or 2 (23.6%) dose adjustments. Three or
more dose adjustments were required in only 16.1% of
patients. The proportion of patients taking each dose of
RLAI over the 24-months is presented in Figure 1.
Similar to the ITT population, the majority of patients in
the PP population were initiated on 25 mg RLAI (89.4%).
The mean dose at baseline was 26.6 ± 5.2 mg, which
increased to 43.6 ± 15.7 mg at 24 months. A greater






Age (years, mean ± SD) 37.1 ± 12.5; 39.3 ± 13
(range) 18 to 26 not reported
Sex, n (%)
Male 547 (69.8%) 246 (68.5%)
Female 237 (30.2%) 113 (31.5%)
Diagnosis
Schizophrenia 580 (74.0%) 266 (74.1%)
Schizoaffective disorder 175 (22.3%) 84 (23.4%)
Other 29 (3.7%) 9 (2.5%)
Time since diagnosis (years, mean ± SD) 10.6 ± 9.5 12.2 ± 10.4
Unemployed, n (%) 705 (89.9%) 319 (88.9%)
CGI-S score (mean ± SD) 4.52 ± 1.04 4.48 ± 1.04
Mean GAF score (mean ± SD) 42.9 ± 14.5 42.3 ± 14.5
Community treatment order 394 (50.3%) 188 (52.3%)
Full hospitalisations in previous 12-months 604 (77.0%) 267 (74.4%)
CGI-S clinical global impression–severity; GAF global assessment of functioning







































Figure 1 Proportion of patients on each dose of RLAI over
time (N = 784 at baseline). The proportion of patients on 12.5 mg
was 0.5% at 1 month, 0.4% at 2, 6 and 7 months, 0.3% at 3 months,
0.2% at 4, 5 and 8 months. All other time points were 0%. RLAI,
risperidone long-acting injection.
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than none (22.3%), 1 (25.3%), or 3 or more (24.0%).
Other psychiatric medications
For PP patients with 24 months of follow up, there was
a decrease in the use of other psychiatric medications
over the course of the study (70.3% at baseline vs. 64.3%
at 24-months, p = 0.048). There was a reduction in ben-
zodiazepine use (42.3% at baseline vs. 29.7% at 24-
months, p < 0.001), a non-significant increase in the use
of antidepressants (16.9% at baseline vs. 18% at 24-
months, p = 0.71), and a reduction in concurrent antic-
holinergics (22% at baseline vs. 16% at 24-months, p =
0.026). There was no marked change in the use of mood
stabilisers or somatic medications. As the percentage of
patients at baseline using other psychiatric medications
was similar between the ITT (71.0%) and PP (70.3%)
populations, the PP population is considered a represen-
tative subpopulation of the ITT.
Illness characteristics
A significant reduction in mean CGI-S score occurred
over the 24-month period (from 4.48 ± 1.04 at baseline to
3.59 ± 1.09 at 24-months; p < 0.001; Figure 2). The major-
ity of this reduction was seen in the first 3-months and
sustained over the 24-month period. This pattern was
reflected in the GAF scores, which improved significantly
over the 24-month period (from 42.3 ± 14.5 at baseline to
58.7 ± 15.3 at 24-months; p < 0.001). Again, the majority
of change occurred within the first 3-months and was sus-
tained over the full 24-month period (Figure 3). Similarly,
the ITT results were: 4.52 ± 1.04 at baseline to 3.56 ± 1.10
at 24-months. And, were also reflected in the improve-
ment in GAF scores over 24-months: 42.9 ± 14.5 at base-
line to 59 ± 15.4 at 24-months.
Hospitalisations
At baseline, 51.1% of patients were being treated on an
in-patient basis. During the 12-months post baseline
(using discharge date as the baseline for inpatients),
48.5% of patients were fully hospitalised at least once, as
opposed to 77% in the 12-months prior to baseline (p <
0.001). The percentage of patients fully hospitalised at
least once post baseline increased from 48.5% at 12-
months to 58.1% at 24-months. However, if the initia-
tion date of RLAI is used as a baseline for all patients,
70.2% of patients were fully hospitalised at least once in
the first 12-months (including the initial episode). And,
by 24-months, the percentage of patients fully hospita-
lised increased slightly to 73.5%. Only patients with data
at the specified time point were included in the analyses
(i.e., completers only).
Clinical deterioration
There was a significant reduction in the proportion of
patient rehospitalisations from baseline to 24-months
(ITT, 54.2% at baseline vs. 12.7% at 24-months; PP,
47.9% at baseline vs. 12.7% at 24-months, p < 0.001
McNemar’s test). There was also a significant reduction
in the proportion of patients who were suicidal or
exhibited homicidal ideation (ITT: 7.9% at baseline vs.
2.3% at 24-months; PP, 7.6% at baseline vs. 2.3% at 24-
months, p = 0.001). Although improved at 24-months
compared with baseline, violent behaviour (p = 0.84)
and self-injury (p = 0.18) did not show a significant
change over the same time period.
Discontinuation of treatment
The Kaplan-Meier estimate for the percentage of ITT
patients who discontinued RLAI before 24-months was
66.7% (95% CI: 63.2% to 70.2%; Figure 4). For the PP
population, the Kaplan-Meier estimate was 46.0% (95%

































Figure 2 CGI-S Score over time - all patients. *Time points were
significantly different from baseline (p < 0.001). CGI-S, clinical global
impression–severity.
























Figure 3 GAF Score over time–all patients.* T i m ep o i n t sw e r e
significantly different from baseline (p < 0.001). GAF, global
assessment of functioning.
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lysis who discontinued RLAI before 24-months the
mean time to discontinuation was 239 ± 180 days. The
main reasons cited for discontinuation were insufficient
response to treatment (25.8%) and lost to follow-up
(23.7%). Excluding patients with lost to follow-up given
as the reason for RLAI discontinuation (i.e. patients
with no 24-month follow-up); the rate decreases to 46%.
The most frequently prescribed antipsychotic at the
time of discontinuation of RLAI was oral risperidone
(21.6%) either alone (15.3%) or in combination with
other antipsychotics (6.3%). Other agents frequently pre-
scribed (either alone or in combination) were olanzapine
(9.5%), clozapine (9.1%) and zuclopenthixol (8.1%).
Adverse events
There were 2273 adverse events reported by 411 (52.4%)
patients in the ITT population during the prospective
24-month period of the study. Relationship to RLAI was
not reported. The most common events (occurring in >
5% patients) were sedation (10.3%), increased weight
(8.7%), headache (7.1%), and tremor (6.5%). Sixty-seven
(8.6%) patients reported 153 serious adverse events. The
most common (occurring in > 1% of patients) were sui-
cidal ideation (1.4%), death (1.3%), and hospitalisation
(1.0%).
Of the 359 patients in the PP population, 194 (54.0%)
received RLAI for at least 24-months. A total of 628
events were reported by 109 (56.2%) patients who were
still receiving RLAI at study end. The most common
events (occurring in > 5% patients) were increased
weight (12.4%), sedation and headache (8.2%), tremor
(7.7%), akathisia (7.7%), insomnia (5.2%), dyspnoea
(5.2%) and vomiting (5.2%). Nineteen (9.8%) patients
who received RLAI at study end reported 44 serious
adverse events. The most common (occurring in ≥ 1%
of patients) were hospitalisation (1.5%), suicidal ideation
(1.5%) pneumonia (1.0%), intentional overdose (1.0%),
overdose (1.0%), aggression (1.0%) and suicide attempt
(1.0%).
Discussion
The patients recruited into the e-STAR study are repre-
sentative of the general population of patients with schi-
zophrenia or schizoaffective disorder in Australia,
although we possibly included a higher proportion of
patients with schizoaffective disorder (22% cf 15% in
previous reports [7,11]). However, they were similar in
age, sex and duration of illness to those reported in the
SOHO study [12]. They were also similar in age, sex,
duration of illness and disease severity to those reported
in the Spanish report of the e-STAR study [7]. One of
the difficulties of research in this area is that a propor-
tion of eligible participants refuse to provide informed
consent. As we did not keep a screening log, we are
unable to determine what proportion of eligible partici-
pants chose not to participate.
One of the important findings of this study is its sup-
port of recent findings by Viner and colleagues [13] in
that many patients with chronic schizophrenia or schi-
zoaffective disorder may benefit from an up-titration
from 25 mg to 37.5 or 50 mg. Viner and colleagues [13]
suggest that although 25 mg is frequently the initial
RLAI dose many patients require at least 37.5 mg, if not
50 mg, for symptom improvement. To achieve maximal
clinical efficacy we found the most common number of
titrations was 2 with an increasing proportion of
patients on 37.5 and 50 mg dosages during the time-
course of the study.
Patients receiving RLAI demonstrated improvements
in CGI-S over the duration of the study - with a change
in mean category from 4 - ‘moderately ill’ to 3 - ‘mildly
ill’. This correlates with a change in BPRS score from
40-45 to 32-36, or a reduction of approximately 10
points [14], indicating a clinically significant change.
Considering that reductionsi nC G I - Ss c o r e sf o rm o r e
severely ill patients are potentially more important, this
finding is clinically notable. This sub-group of ill
patients are likely to experience a greater number of
symptoms, and reductions are likely to correlate with
more substantial symptom improvement, especially
given the possibility of ceiling effects [14]. The improve-
ment observed is similar to previously reported reduc-
tions in CGI-S scores at 3-months of between 0.5 and
0.9 following initiation of RLAI in patients with schizo-
phrenia [15], and is consistent with the findings of the
Spanish e-STAR investigators who reported a reduction
in CGI-S score of 1.14 points [7].
Recently, the GAF scale has been validated on the
domains of psychological, social and occupational func-






























Figure 4 Time to discontinuation of RLAI (n = 784).
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- a significant improvement in patient functioning. This
is consistent with the findings of the Spanish e-STAR
investigators who reported an increase in GAF score of
17.3 points [7].
The mechanisms responsible for improvements in dis-
ease severity and functioning were not assessed in our
study, however, we hypothesize that improvements were
due to improved adherence with antipsychotic medica-
tion, as has been reported by others [17-19].
Although initiation of RLAI resulted in an overall
decrease in the percentage of patients using other psy-
chiatric medications, the changes in concomitant medi-
cation use reported in this study are complicated by the
collection technique we used to gather these data (a
simple tick box of whether the medication had been
used in the previous 3-months). As such, we are unable
to separate medications taken during an acute admis-
sion, such as benzodiazepines, from those that were pre-
scribed on a long-term basis. We know that patients are
prescribed benzodiazepines as an alternative to neuro-
leptic treatment in acute psychosis [20]. Lambert and
colleagues [20] report that benzodiazepines are pre-
scribed for 17% of patients prior to admission, peaking
at 42% on the first day of admission and reducing to
28% at the time of discharge.
Initiation of RLAI significantly reduced the number
of hospitalisations for patients who remained on treat-
ment for 12 and 24 months. This again reflects the
findings of the Spanish e-STAR investigators [7]. This
finding has potential implications for health care costs
in the long-term management of schizophrenia. Addi-
tionally, it suggests there may be considerable cost sav-
ings over a 24-month period through reduced
hospitalisation [21].
The treatment discontinuation rate in this study is
high compared to that observed in the RLAI Spanish
cohort of the e-STAR study at 24-months: 66.7%
vs18.2% [7]. It is not clear why there is this difference in
discontinuation between the two countries: baseline
demographics were similar in the two cohorts. It may
reflect different mental health policies between the two
countries, or the itinerant nature of the Australian
population. The seemingly poor RLAI retention rate
observed in this study, although improved for patients
who completed the full 24-month period, may be
explained by the population being more treatment resis-
tant, as shown by the choice of post-RLAI antipsychotic
treatment. Oral risperidone, olanzapine, clozapine, and
zuclopenthixol, alone or in combination, were the most
frequently prescribed medications post-RLAI. Further-
more, it is well known patients participating in antipsy-
chotic treatment studies tend to have high dropout rates
[22,23]. There was little difference between baseline
characteristics of those who completed the study com-
pared to the overall study population (with the excep-
tion that the duration of diagnosis was longer in the
completer population). Clozapine, the treatment of
choice for treatment-resistant patients, was frequently
prescribed post-discontinuation of RLAI (9.1%). How-
ever, the proportion of patients receiving combinations
of antipsychotic therapies suggests that some were resis-
tant to treatment, and therefore likely to be non-
adherent.
The adverse event profile was as to be expected in this
patient population [9,15,24].
A prominent limitation of this study is the lack of a
control arm. The data in this paper are from Australia
only, and differences in culture and health care systems
may mean our results are not generalisable to other
countries. However, our results do support those
reported by the Spanish e-STAR group [7]. That said,
the population observed is consistent with that seen in
Australian practice and is therefore relevant to clinicians
in Australia. Furthermore, it should be emphasised that
this study was naturalistic (observational), containing
both retrospective and prospective elements, however,
as it was not blinded, there is the possibility of observa-
tional bias.
Conclusion
The data generated from the e-STAR Australian cohort
shows RLAI treatment is associated with early improve-
ments in illness severity and patient functioning, and
these improvements are sustained at 24-months. RLAI
treatment was also associated with a decrease in hospi-
talisation rates and in the use of concomitant psychotro-
pic medication.
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